Main Logo
+17162654855
[email protected]

Strategic Insights for Microbiome CDMO Market Growth

Microbiome CDMO by Application (Vaccine R&D, Biopharmaceutical, Cell Therapy, Others), by Types (Microbial CDMO, Antibiotic CDMO, Phage CDMO, Bacteriocins CDMO), by North America (United States, Canada, Mexico), by South America (Brazil, Argentina, Rest of South America), by Europe (United Kingdom, Germany, France, Italy, Spain, Russia, Benelux, Nordics, Rest of Europe), by Middle East & Africa (Turkey, Israel, GCC, North Africa, South Africa, Rest of Middle East & Africa), by Asia Pacific (China, India, Japan, South Korea, ASEAN, Oceania, Rest of Asia Pacific) Forecast 2026-2034

Base Year: 2025
122 Pages
Main Logo

Strategic Insights for Microbiome CDMO Market Growth

About Precision Market View

Precision Market View offers precise market research, industry intelligence, and data analysis for healthcare, manufacturing, technology, and energy. Our reports provide the clarity you need to make informed decisions and drive growth.

Our team combines primary research, advanced analytics, and industry expertise to deliver actionable intelligence. We offer syndicated reports, custom research, and consulting services tailored to your business needs.

At Precision Market View, we are committed to quality, transparency, and client satisfaction. Every report is rigorously validated to ensure accuracy and relevance. Our global perspective and local expertise help you understand both the big picture and the finer details of your market.

Stay informed with Precision Market View. Subscribe to our newsletter for the latest updates and research highlights, and follow us on social media for real-time insights.

Precision Market View – Clarity for Your Strategic Decisions.

Geographic Coverage of Microbiome CDMO

Higher Coverage
Lower Coverage
No Coverage

Microbiome CDMO REPORT HIGHLIGHTS

AspectsDetails
Study Period 2020-2034
Base Year 2025
Estimated Year 2026
Forecast Period2026-2034
Historical Period2020-2025
Growth RateCAGR of 9.8% from 2020-2034
Segmentation
    • By Application
      • Vaccine R&D
      • Biopharmaceutical
      • Cell Therapy
      • Others
    • By Types
      • Microbial CDMO
      • Antibiotic CDMO
      • Phage CDMO
      • Bacteriocins CDMO
  • By Geography
    • North America
      • United States
      • Canada
      • Mexico
    • South America
      • Brazil
      • Argentina
      • Rest of South America
    • Europe
      • United Kingdom
      • Germany
      • France
      • Italy
      • Spain
      • Russia
      • Benelux
      • Nordics
      • Rest of Europe
    • Middle East & Africa
      • Turkey
      • Israel
      • GCC
      • North Africa
      • South Africa
      • Rest of Middle East & Africa
    • Asia Pacific
      • China
      • India
      • Japan
      • South Korea
      • ASEAN
      • Oceania
      • Rest of Asia Pacific

Table of Contents

  1. 1. Introduction
    • 1.1. Research Scope
    • 1.2. Market Segmentation
    • 1.3. Research Objective
    • 1.4. Definitions and Assumptions
  2. 2. Executive Summary
    • 2.1. Market Snapshot
  3. 3. Market Dynamics
    • 3.1. Market Drivers
    • 3.2. Market Restrains
    • 3.3. Market Trends
    • 3.4. Market Opportunities
  4. 4. Market Factor Analysis
    • 4.1. Porters Five Forces
      • 4.1.1. Bargaining Power of Suppliers
      • 4.1.2. Bargaining Power of Buyers
      • 4.1.3. Threat of New Entrants
      • 4.1.4. Threat of Substitutes
      • 4.1.5. Competitive Rivalry
    • 4.2. PESTEL analysis
    • 4.3. BCG Analysis
      • 4.3.1. Stars (High Growth, High Market Share)
      • 4.3.2. Cash Cows (Low Growth, High Market Share)
      • 4.3.3. Question Mark (High Growth, Low Market Share)
      • 4.3.4. Dogs (Low Growth, Low Market Share)
    • 4.4. Ansoff Matrix Analysis
    • 4.5. Supply Chain Analysis
    • 4.6. Regulatory Landscape
    • 4.7. Current Market Potential and Opportunity Assessment (TAM–SAM–SOM Framework)
    • 4.8. PMV Analyst Note
  5. 5. Market Analysis, Insights and Forecast 2021-2033
    • 5.1. Market Analysis, Insights and Forecast - by Application
      • 5.1.1. Vaccine R&D
      • 5.1.2. Biopharmaceutical
      • 5.1.3. Cell Therapy
      • 5.1.4. Others
    • 5.2. Market Analysis, Insights and Forecast - by Types
      • 5.2.1. Microbial CDMO
      • 5.2.2. Antibiotic CDMO
      • 5.2.3. Phage CDMO
      • 5.2.4. Bacteriocins CDMO
    • 5.3. Market Analysis, Insights and Forecast - by Region
      • 5.3.1. North America
      • 5.3.2. South America
      • 5.3.3. Europe
      • 5.3.4. Middle East & Africa
      • 5.3.5. Asia Pacific
  6. 6. Global Microbiome CDMO Analysis, Insights and Forecast, 2021-2033
    • 6.1. Market Analysis, Insights and Forecast - by Application
      • 6.1.1. Vaccine R&D
      • 6.1.2. Biopharmaceutical
      • 6.1.3. Cell Therapy
      • 6.1.4. Others
    • 6.2. Market Analysis, Insights and Forecast - by Types
      • 6.2.1. Microbial CDMO
      • 6.2.2. Antibiotic CDMO
      • 6.2.3. Phage CDMO
      • 6.2.4. Bacteriocins CDMO
  7. 7. North America Microbiome CDMO Analysis, Insights and Forecast, 2020-2032
    • 7.1. Market Analysis, Insights and Forecast - by Application
      • 7.1.1. Vaccine R&D
      • 7.1.2. Biopharmaceutical
      • 7.1.3. Cell Therapy
      • 7.1.4. Others
    • 7.2. Market Analysis, Insights and Forecast - by Types
      • 7.2.1. Microbial CDMO
      • 7.2.2. Antibiotic CDMO
      • 7.2.3. Phage CDMO
      • 7.2.4. Bacteriocins CDMO
  8. 8. South America Microbiome CDMO Analysis, Insights and Forecast, 2020-2032
    • 8.1. Market Analysis, Insights and Forecast - by Application
      • 8.1.1. Vaccine R&D
      • 8.1.2. Biopharmaceutical
      • 8.1.3. Cell Therapy
      • 8.1.4. Others
    • 8.2. Market Analysis, Insights and Forecast - by Types
      • 8.2.1. Microbial CDMO
      • 8.2.2. Antibiotic CDMO
      • 8.2.3. Phage CDMO
      • 8.2.4. Bacteriocins CDMO
  9. 9. Europe Microbiome CDMO Analysis, Insights and Forecast, 2020-2032
    • 9.1. Market Analysis, Insights and Forecast - by Application
      • 9.1.1. Vaccine R&D
      • 9.1.2. Biopharmaceutical
      • 9.1.3. Cell Therapy
      • 9.1.4. Others
    • 9.2. Market Analysis, Insights and Forecast - by Types
      • 9.2.1. Microbial CDMO
      • 9.2.2. Antibiotic CDMO
      • 9.2.3. Phage CDMO
      • 9.2.4. Bacteriocins CDMO
  10. 10. Middle East & Africa Microbiome CDMO Analysis, Insights and Forecast, 2020-2032
    • 10.1. Market Analysis, Insights and Forecast - by Application
      • 10.1.1. Vaccine R&D
      • 10.1.2. Biopharmaceutical
      • 10.1.3. Cell Therapy
      • 10.1.4. Others
    • 10.2. Market Analysis, Insights and Forecast - by Types
      • 10.2.1. Microbial CDMO
      • 10.2.2. Antibiotic CDMO
      • 10.2.3. Phage CDMO
      • 10.2.4. Bacteriocins CDMO
  11. 11. Asia Pacific Microbiome CDMO Analysis, Insights and Forecast, 2020-2032
    • 11.1. Market Analysis, Insights and Forecast - by Application
      • 11.1.1. Vaccine R&D
      • 11.1.2. Biopharmaceutical
      • 11.1.3. Cell Therapy
      • 11.1.4. Others
    • 11.2. Market Analysis, Insights and Forecast - by Types
      • 11.2.1. Microbial CDMO
      • 11.2.2. Antibiotic CDMO
      • 11.2.3. Phage CDMO
      • 11.2.4. Bacteriocins CDMO
  12. 12. Competitive Analysis
      • 12.1. Company Profiles
        • 12.1.1 Arranta Bio
          • 12.1.1.1. Company Overview
          • 12.1.1.2. Products
          • 12.1.1.3. Company Financials
          • 12.1.1.4. SWOT Analysis
        • 12.1.2 Wacker Chemie AG
          • 12.1.2.1. Company Overview
          • 12.1.2.2. Products
          • 12.1.2.3. Company Financials
          • 12.1.2.4. SWOT Analysis
        • 12.1.3 Bactera
          • 12.1.3.1. Company Overview
          • 12.1.3.2. Products
          • 12.1.3.3. Company Financials
          • 12.1.3.4. SWOT Analysis
        • 12.1.4 SGS Quay Pharma
          • 12.1.4.1. Company Overview
          • 12.1.4.2. Products
          • 12.1.4.3. Company Financials
          • 12.1.4.4. SWOT Analysis
        • 12.1.5 Biose
          • 12.1.5.1. Company Overview
          • 12.1.5.2. Products
          • 12.1.5.3. Company Financials
          • 12.1.5.4. SWOT Analysis
        • 12.1.6 EnteroBiotix
          • 12.1.6.1. Company Overview
          • 12.1.6.2. Products
          • 12.1.6.3. Company Financials
          • 12.1.6.4. SWOT Analysis
        • 12.1.7 Genome And Company
          • 12.1.7.1. Company Overview
          • 12.1.7.2. Products
          • 12.1.7.3. Company Financials
          • 12.1.7.4. SWOT Analysis
        • 12.1.8 Lallemand Health Solutions
          • 12.1.8.1. Company Overview
          • 12.1.8.2. Products
          • 12.1.8.3. Company Financials
          • 12.1.8.4. SWOT Analysis
        • 12.1.9 List Bio
          • 12.1.9.1. Company Overview
          • 12.1.9.2. Products
          • 12.1.9.3. Company Financials
          • 12.1.9.4. SWOT Analysis
        • 12.1.10 Rise BioServices
          • 12.1.10.1. Company Overview
          • 12.1.10.2. Products
          • 12.1.10.3. Company Financials
          • 12.1.10.4. SWOT Analysis
        • 12.1.11 Lonza
          • 12.1.11.1. Company Overview
          • 12.1.11.2. Products
          • 12.1.11.3. Company Financials
          • 12.1.11.4. SWOT Analysis
        • 12.1.12 MaaT Pharma
          • 12.1.12.1. Company Overview
          • 12.1.12.2. Products
          • 12.1.12.3. Company Financials
          • 12.1.12.4. SWOT Analysis
        • 12.1.13 NIZO
          • 12.1.13.1. Company Overview
          • 12.1.13.2. Products
          • 12.1.13.3. Company Financials
          • 12.1.13.4. SWOT Analysis
        • 12.1.14 Quay Pharmaceuticals
          • 12.1.14.1. Company Overview
          • 12.1.14.2. Products
          • 12.1.14.3. Company Financials
          • 12.1.14.4. SWOT Analysis
        • 12.1.15 Recipharm
          • 12.1.15.1. Company Overview
          • 12.1.15.2. Products
          • 12.1.15.3. Company Financials
          • 12.1.15.4. SWOT Analysis
      • 12.2. Market Entropy
        • 12.2.1 Company's Key Areas Served
        • 12.2.2 Recent Developments
      • 12.3. Company Market Share Analysis 2025
        • 12.3.1 Top 5 Companies Market Share Analysis
        • 12.3.2 Top 3 Companies Market Share Analysis
    • 12.4. List of Potential Customers
  13. 13. Research Methodology

    List of Figures

    1. Figure 1: Global Microbiome CDMO Revenue Breakdown (million, %) by Region 2025 & 2033
    2. Figure 2: North America Microbiome CDMO Revenue (million), by Application 2025 & 2033
    3. Figure 3: North America Microbiome CDMO Revenue Share (%), by Application 2025 & 2033
    4. Figure 4: North America Microbiome CDMO Revenue (million), by Types 2025 & 2033
    5. Figure 5: North America Microbiome CDMO Revenue Share (%), by Types 2025 & 2033
    6. Figure 6: North America Microbiome CDMO Revenue (million), by Country 2025 & 2033
    7. Figure 7: North America Microbiome CDMO Revenue Share (%), by Country 2025 & 2033
    8. Figure 8: South America Microbiome CDMO Revenue (million), by Application 2025 & 2033
    9. Figure 9: South America Microbiome CDMO Revenue Share (%), by Application 2025 & 2033
    10. Figure 10: South America Microbiome CDMO Revenue (million), by Types 2025 & 2033
    11. Figure 11: South America Microbiome CDMO Revenue Share (%), by Types 2025 & 2033
    12. Figure 12: South America Microbiome CDMO Revenue (million), by Country 2025 & 2033
    13. Figure 13: South America Microbiome CDMO Revenue Share (%), by Country 2025 & 2033
    14. Figure 14: Europe Microbiome CDMO Revenue (million), by Application 2025 & 2033
    15. Figure 15: Europe Microbiome CDMO Revenue Share (%), by Application 2025 & 2033
    16. Figure 16: Europe Microbiome CDMO Revenue (million), by Types 2025 & 2033
    17. Figure 17: Europe Microbiome CDMO Revenue Share (%), by Types 2025 & 2033
    18. Figure 18: Europe Microbiome CDMO Revenue (million), by Country 2025 & 2033
    19. Figure 19: Europe Microbiome CDMO Revenue Share (%), by Country 2025 & 2033
    20. Figure 20: Middle East & Africa Microbiome CDMO Revenue (million), by Application 2025 & 2033
    21. Figure 21: Middle East & Africa Microbiome CDMO Revenue Share (%), by Application 2025 & 2033
    22. Figure 22: Middle East & Africa Microbiome CDMO Revenue (million), by Types 2025 & 2033
    23. Figure 23: Middle East & Africa Microbiome CDMO Revenue Share (%), by Types 2025 & 2033
    24. Figure 24: Middle East & Africa Microbiome CDMO Revenue (million), by Country 2025 & 2033
    25. Figure 25: Middle East & Africa Microbiome CDMO Revenue Share (%), by Country 2025 & 2033
    26. Figure 26: Asia Pacific Microbiome CDMO Revenue (million), by Application 2025 & 2033
    27. Figure 27: Asia Pacific Microbiome CDMO Revenue Share (%), by Application 2025 & 2033
    28. Figure 28: Asia Pacific Microbiome CDMO Revenue (million), by Types 2025 & 2033
    29. Figure 29: Asia Pacific Microbiome CDMO Revenue Share (%), by Types 2025 & 2033
    30. Figure 30: Asia Pacific Microbiome CDMO Revenue (million), by Country 2025 & 2033
    31. Figure 31: Asia Pacific Microbiome CDMO Revenue Share (%), by Country 2025 & 2033

    List of Tables

    1. Table 1: Global Microbiome CDMO Revenue million Forecast, by Application 2020 & 2033
    2. Table 2: Global Microbiome CDMO Revenue million Forecast, by Types 2020 & 2033
    3. Table 3: Global Microbiome CDMO Revenue million Forecast, by Region 2020 & 2033
    4. Table 4: Global Microbiome CDMO Revenue million Forecast, by Application 2020 & 2033
    5. Table 5: Global Microbiome CDMO Revenue million Forecast, by Types 2020 & 2033
    6. Table 6: Global Microbiome CDMO Revenue million Forecast, by Country 2020 & 2033
    7. Table 7: United States Microbiome CDMO Revenue (million) Forecast, by Application 2020 & 2033
    8. Table 8: Canada Microbiome CDMO Revenue (million) Forecast, by Application 2020 & 2033
    9. Table 9: Mexico Microbiome CDMO Revenue (million) Forecast, by Application 2020 & 2033
    10. Table 10: Global Microbiome CDMO Revenue million Forecast, by Application 2020 & 2033
    11. Table 11: Global Microbiome CDMO Revenue million Forecast, by Types 2020 & 2033
    12. Table 12: Global Microbiome CDMO Revenue million Forecast, by Country 2020 & 2033
    13. Table 13: Brazil Microbiome CDMO Revenue (million) Forecast, by Application 2020 & 2033
    14. Table 14: Argentina Microbiome CDMO Revenue (million) Forecast, by Application 2020 & 2033
    15. Table 15: Rest of South America Microbiome CDMO Revenue (million) Forecast, by Application 2020 & 2033
    16. Table 16: Global Microbiome CDMO Revenue million Forecast, by Application 2020 & 2033
    17. Table 17: Global Microbiome CDMO Revenue million Forecast, by Types 2020 & 2033
    18. Table 18: Global Microbiome CDMO Revenue million Forecast, by Country 2020 & 2033
    19. Table 19: United Kingdom Microbiome CDMO Revenue (million) Forecast, by Application 2020 & 2033
    20. Table 20: Germany Microbiome CDMO Revenue (million) Forecast, by Application 2020 & 2033
    21. Table 21: France Microbiome CDMO Revenue (million) Forecast, by Application 2020 & 2033
    22. Table 22: Italy Microbiome CDMO Revenue (million) Forecast, by Application 2020 & 2033
    23. Table 23: Spain Microbiome CDMO Revenue (million) Forecast, by Application 2020 & 2033
    24. Table 24: Russia Microbiome CDMO Revenue (million) Forecast, by Application 2020 & 2033
    25. Table 25: Benelux Microbiome CDMO Revenue (million) Forecast, by Application 2020 & 2033
    26. Table 26: Nordics Microbiome CDMO Revenue (million) Forecast, by Application 2020 & 2033
    27. Table 27: Rest of Europe Microbiome CDMO Revenue (million) Forecast, by Application 2020 & 2033
    28. Table 28: Global Microbiome CDMO Revenue million Forecast, by Application 2020 & 2033
    29. Table 29: Global Microbiome CDMO Revenue million Forecast, by Types 2020 & 2033
    30. Table 30: Global Microbiome CDMO Revenue million Forecast, by Country 2020 & 2033
    31. Table 31: Turkey Microbiome CDMO Revenue (million) Forecast, by Application 2020 & 2033
    32. Table 32: Israel Microbiome CDMO Revenue (million) Forecast, by Application 2020 & 2033
    33. Table 33: GCC Microbiome CDMO Revenue (million) Forecast, by Application 2020 & 2033
    34. Table 34: North Africa Microbiome CDMO Revenue (million) Forecast, by Application 2020 & 2033
    35. Table 35: South Africa Microbiome CDMO Revenue (million) Forecast, by Application 2020 & 2033
    36. Table 36: Rest of Middle East & Africa Microbiome CDMO Revenue (million) Forecast, by Application 2020 & 2033
    37. Table 37: Global Microbiome CDMO Revenue million Forecast, by Application 2020 & 2033
    38. Table 38: Global Microbiome CDMO Revenue million Forecast, by Types 2020 & 2033
    39. Table 39: Global Microbiome CDMO Revenue million Forecast, by Country 2020 & 2033
    40. Table 40: China Microbiome CDMO Revenue (million) Forecast, by Application 2020 & 2033
    41. Table 41: India Microbiome CDMO Revenue (million) Forecast, by Application 2020 & 2033
    42. Table 42: Japan Microbiome CDMO Revenue (million) Forecast, by Application 2020 & 2033
    43. Table 43: South Korea Microbiome CDMO Revenue (million) Forecast, by Application 2020 & 2033
    44. Table 44: ASEAN Microbiome CDMO Revenue (million) Forecast, by Application 2020 & 2033
    45. Table 45: Oceania Microbiome CDMO Revenue (million) Forecast, by Application 2020 & 2033
    46. Table 46: Rest of Asia Pacific Microbiome CDMO Revenue (million) Forecast, by Application 2020 & 2033

    Frequently Asked Questions

    1. What is the projected Compound Annual Growth Rate (CAGR) of the Microbiome CDMO?

    The projected CAGR is approximately 9.8%.

    2. Which companies are prominent players in the Microbiome CDMO?

    Key companies in the market include Arranta Bio, Wacker Chemie AG, Bactera, SGS Quay Pharma, Biose, EnteroBiotix, Genome And Company, Lallemand Health Solutions, List Bio, Rise BioServices, Lonza, MaaT Pharma, NIZO, Quay Pharmaceuticals, Recipharm.

    3. What are the main segments of the Microbiome CDMO?

    The market segments include Application, Types.

    4. Can you provide details about the market size?

    The market size is estimated to be USD 1431 million as of 2022.

    5. What are some drivers contributing to market growth?

    N/A

    6. What are the notable trends driving market growth?

    N/A

    7. Are there any restraints impacting market growth?

    N/A

    8. Can you provide examples of recent developments in the market?

    N/A

    9. What pricing options are available for accessing the report?

    Pricing options include single-user, multi-user, and enterprise licenses priced at USD 4350.00, USD 6525.00, and USD 8700.00 respectively.

    10. Is the market size provided in terms of value or volume?

    The market size is provided in terms of value, measured in million.

    11. Are there any specific market keywords associated with the report?

    Yes, the market keyword associated with the report is "Microbiome CDMO," which aids in identifying and referencing the specific market segment covered.

    12. How do I determine which pricing option suits my needs best?

    The pricing options vary based on user requirements and access needs. Individual users may opt for single-user licenses, while businesses requiring broader access may choose multi-user or enterprise licenses for cost-effective access to the report.

    13. Are there any additional resources or data provided in the Microbiome CDMO report?

    While the report offers comprehensive insights, it's advisable to review the specific contents or supplementary materials provided to ascertain if additional resources or data are available.

    14. How can I stay updated on further developments or reports in the Microbiome CDMO?

    To stay informed about further developments, trends, and reports in the Microbiome CDMO, consider subscribing to industry newsletters, following relevant companies and organizations, or regularly checking reputable industry news sources and publications.

    Methodology

    Step 1 - Identification of Relevant Samples Size from Population Database

    Step Chart
    Bar Chart
    Method Chart

    Step 2 - Approaches for Defining Global Market Size (Value, Volume* & Price*)

    Approach Chart
    Top-down and bottom-up approaches are used to validate the global market size and estimate the market size for manufactures, regional segments, product, and application.

    Note*: In applicable scenarios

    Step 3 - Data Sources

    Primary Research

    • Web Analytics
    • Survey Reports
    • Research Institute
    • Latest Research Reports
    • Opinion Leaders

    Secondary Research

    • Annual Reports
    • White Paper
    • Latest Press Release
    • Industry Association
    • Paid Database
    • Investor Presentations
    Analyst Chart

    Step 4 - Data Triangulation

    Involves using different sources of information in order to increase the validity of a study

    These sources are likely to be stakeholders in a program - participants, other researchers, program staff, other community members, and so on.

    Then we put all data in single framework & apply various statistical tools to find out the dynamic on the market.

    During the analysis stage, feedback from the stakeholder groups would be compared to determine areas of agreement as well as areas of divergence

    Additionally, after gathering mixed and scattered data from a wide range of sources, data is triangulated and correlated to come up with estimated figures which are further validated through primary mediums or industry experts, opinion leaders.